RA Literature Highlights – March 2023
Tofacitinib, Baricitinib, Sarilumab, bDMARDs, tsDMARDs, BSRBR-RA
Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
September 2022
Upadacitinib as Monotherapy and in Combination With Non-biologic Disease-modifying Antirheumatic Drugs for Psoriatic Arthritis
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab905
In this investigation, upadacitinib showed comparable efficacy as monotherapy and in combination with nbDMARDs in PsA. In coming to this conclusion investigators aimed to assess the efficacy and safety of upadacitinib as monotherapy or in combination with nbDMARDs in patients with PsA.